



Next-Generation Sequencing Technologies in Solid Tumor

Guest Editor:

Dr. Francesca Duraturo

Department of Advanced
Biomedical Sciences, University
of Naples Federico II, 80131
Naples, Italy

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editor

The application of next-generation sequencing (NGS) technologies in investigations of solid tumors has allowed us to obtain the maximum genomic evaluation of the tumor. Furthermore, the application of NGS technologies on the genome/exome of affected subjects and with a positive family history of cancer has allowed the identification of a large number of genes responsible for familial/hereditary forms of cancer. NGS approaches involve DNA and RNA analysis. DNA sequencing deals with revealing nucleotide variants on a selection of genes of interest for a specific tumor area. RNA sequencing allows detection of alternative genetic transcripts, post-transcriptional modifications, gene fusion, single nucleotide mutations/polymorphisms, small and long non-coding RNAs, and changes in gene expression. Most of the applications are in the field of cancer research, but NGS technology is also widely used in molecular diagnostics.

In this Special Issue, we would like to collect recent diagnostic/predictive clinical findings obtained from NGS applications to various solid tumors and on the genome/germinal exome of subjects affected by familial/hereditary cancers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)